ENTREPNEW - New Ideas and Innovation: Next Big Future

Sunday, March 9, 2014

Next Big Future - 2 new articles

The advances/new ideas as I have mentioned in class will come from two sectors:

telecom

health care.

Some of the advances are being exploited all ready by Roche which uses monoclonal (bodies own soldiers ) in the treatment of cancer. Thus the two discussions here are on Genetically Modified T cells and wireless communications. That is the future of telecon. No more submarine cables and unsightly wires and posts.

---------- Forwarded message ----------
From: FeedBlitz <feedblitz@mail.feedblitz.com>
Date: Sun, Mar 2, 2014 at 3:00 PM
Subject: Next Big Future - 2 new articles

Click here to read this mailing online.

Here are the latest updates for jorgeus.george@gmail.com

"Next Big Future" - 2 new articles

Perlman's Artemis pCell Wireless real time beamforming will massively boost wireless communication speed and enable wireless power revolutin

Steve Perlman's Artemis Wireless technology will offer a solution to the "spectrum crunch" problem. From a mobile consumer's standpoint, it'll just seem like the next step in evolution from 4G to 5G - much faster, more consistent speeds, and with lower latency.

New analysis is from Imran Akbars website. I believe Imran Akbar is the VP of Motorola Solutions.

The theory behind the Perlman pCell system system is referred to as "network MIMO" or "cooperative MIMO" in the literature and "coordinated beamforming" in the 3GPP LTE-A specification, and dates back to at least 2001. Artemis has taken techniques that are being proposed for upcoming 5G systems and figured out how to solve all the engineering challenges involved, years ahead of the rest of the industry.

The last slide of the presentation at Columbia says the following:

* "pCell technology is not just limited to communications"
* the "synthesis of a tiny radio-wave bubble in real time software opens up a new wave of applications"

Wireless power transmission will be the next wave of application for real time beamforming.

• Email to a friend • Article Search •

Genetically modified T cells induced complete remissions in 88 percent of advanced leukemia patients treated

Investigators from Memorial Sloan Kettering Cancer Center have reported more encouraging news about one of the most exciting methods of cancer treatment today. The largest clinical study ever conducted to date of patients with advanced leukemia found that 88 percent achieved complete remissions after being treated with genetically modified versions of their own immune cells. The results were published today in Science Translational Medicine.

"These extraordinary results demonstrate that cell therapy is a powerful treatment for patients who have exhausted all conventional therapies," said Michel Sadelain, MD, PhD, Director of the Center for Cell Engineering at Memorial Sloan Kettering and one of the study's senior authors. "Our initial findings have held up in a larger cohort of patients, and we are already looking at new clinical studies to advance this novel therapeutic approach in fighting cancer."

Adult B cell acute lymphoblastic leukemia (B-ALL), a type of blood cancer that develops in B cells, is difficult to treat because the majority of patients relapse. Patients with relapsed B-ALL have few treatment options; only 30 percent respond to salvage chemotherapy. Without a successful bone marrow transplant, few have any hope of long-term survival.

Read more »